Related Experiment Video
Updated: Aug 10, 2026
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 29, 2010
Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas
K Koretz1, S Brüderlein, C Henne
1Institute of Pathology, University of Heidelberg, Germany.
British Journal of Cancer
|November 1, 1992
Summary
Decay-accelerating factor (DAF, CD55) is sporadically expressed on normal colon cells but frequently upregulated on colon adenomas and carcinomas. This upregulation may protect tumor cells from complement-mediated damage.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Decay-accelerating factor (DAF, CD55) is a complement regulatory protein.
- DAF prevents autologous complement cascade activation.
- DAF is found on cells in contact with complement proteins, including tumor cells.
Purpose of the Study:
- To investigate the expression of DAF (CD55) in normal colonic epithelium, adenomas, and colorectal carcinomas.
- To determine if DAF (CD55) expression correlates with tumor characteristics.
Main Methods:
- Immunohistochemical analysis of DAF (CD55) expression.
- Utilized antibodies CD55(BRIC110) and CD55(143-30).
- Examined normal colonic epithelium, 20 adenomas, and 88 colorectal carcinomas, including the HT29 cell line.
Main Results:
- DAF (CD55) expression was sporadic on normal colonic epithelium.
- DAF (CD55) was upregulated in a significant subset of adenomas (10/20) and carcinomas (52/88).
- DAF (CD55) was more frequent in mucinous carcinomas (P = 0.007) but showed no correlation with grading, staging, or location.
Conclusions:
- DAF (CD55) is upregulated in a subset of colorectal adenomas and carcinomas.
- The observed upregulation may indicate a role in protecting tumor cells from complement-mediated cytotoxicity.
- Further investigation is warranted to understand the prognostic implications of DAF (CD55) expression in colorectal cancer.
